Serum HE4 outperformed serum CA125 in predicting endometrial cancer (AUC 0.86, 95% CI 0.77, 0.96, p < 0.001 vs AUC 0.81 (95% CI 0.70, 0.93, p < 0.001) (Figure S2). This evidence concerns the gene MUC16 and endometrial cancer.